Earnings Whisper ®
3rd Quarter September 2022
Revenue: $34.68 Mil
Guidance announcement made Wednesday, August 10, 2022
Wednesday, August 10, 2022
What do you expect when ADMA reports earnings?
Where is ADMA's stock price going from here?
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.